AgingResearch.NewsJoin free

BioAge Labs

CompanyUnited StatesFounded 2015

BioAge Labs develops one asset, in phase 2 (BGE-102 in cardiovascular risk). Mostly small molecule acting on NLRP3, NLRP3 inflammasome and inflammation; based in the United States, founded in 2015.

1
Asset
Furthest stage
Phase 2
Raised
US$485m
1
Grant
1
Trial
0
Signals

Pipeline

1

  • BGE-102

    Orally available, brain-penetrant inhibitor of NLRP3 that reduces inflammatory biomarkers.

    Phase 2, Small molecule, NLRP3, NLRP3 inflammasome, cardiovascular risk, diabetic macular edema

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms4
  • Trials1
  • Funding rounds and grants3
  • Deals2
  • People24
  • Signals3
  • Similar companies6

Papers

Intelligence